Helen Barker

Vice President, Global Tech Ops & CMC, Reneo Pharmaceuticals

With a diverse background in large pharma and biotech companies, Helen leads the successful technical and strategic development of novel compounds, devices, and businesses.

Helen is the Vice President of Global Tech Ops & CMC at Reneo Pharma Ltd., a clinical-stage company focused on the development and commercialisation of therapies for patients with rare, genetic, mitochondrial diseases. She is also the founder and managing director of Project-ion Ltd, which advances the development of small and large molecules with biotech organisations.

She has a proven track record in developing innovative project strategies and their delivery to critical milestones. A leader of global, multidisciplinary teams in CMC, diagnostics, clinical research, and across R&D.

She enjoyed a range of positions within Pfizer, Bristol-Myers Squibb, multiple start-up companies, and the University of Oxford, enabled by degrees in Chemical and Pharmaceutical Science and an MBA. She was Head of Pharmaceutical Development at Ziarco, which Novartis acquired in 2016.

Helen is a Faculty Fellow of the Royal Pharmaceutical Society, a Chartered Chemist, Chartered Scientist and a Fellow of the Royal Society of Chemistry.

Areas of particular expertise include rare and orphan, infectious, and respiratory diseases. Further interests include business strategy development, supporting emerging pharmaceutical scientist leaders, and patient and public involvement in research.


Leonardo Royal Hotel London Tower Bridge

16 May 2023